ATYR
NASDAQaTyr Pharma Inc.
$0.79+0.00 (+0.29%)
News25/Ratings9
Price$0.79-0.01 (-1.10%)
01:30 PM07:45 PM
News · 26 weeks21-100%
2025-11-022026-04-26
Mix1390d
- Other5(38%)
- SEC Filings5(38%)
- Insider3(23%)
Latest news
25 items- SECSEC Form DEFA14A filed by aTyr Pharma Inc.DEFA14A - aTYR PHARMA INC (0001339970) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
- SECSEC Form DEF 14A filed by aTyr Pharma Inc.DEF 14A - aTYR PHARMA INC (0001339970) (Filer)
- SECSEC Form PRE 14A filed by aTyr Pharma Inc.PRE 14A - aTYR PHARMA INC (0001339970) (Filer)
- SECSEC Form 10-K filed by aTyr Pharma Inc.10-K - aTYR PHARMA INC (0001339970) (Filer)
- SECaTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - aTYR PHARMA INC (0001339970) (Filer)
- PRaTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate UpdateCompany scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase pla
- PRaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr's common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on February 17, 2026, the effective date of the grants. These stock awards were granted as an inducement ma
- PRaTyr Pharma to Present at the Leerink Partners Global Healthcare ConferenceSAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL. Details of the presentation appear below: Conference: Leerink Partners Global Healthcare ConferenceDate: Wednesday, March 11, 2026Time: 8:00am EDTLocation: Miami, FLFormat: Corporate Presentation In addition to the presentation, company m
- INSIDERPresident and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERChief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $1,521 worth of shares (1,558 units at $0.98), increasing direct ownership by 6% to 37,296 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERGeneral Counsel Denyes Nancy converted options into 2,687 shares and sold $1,091 worth of shares (1,118 units at $0.98), increasing direct ownership by 5% to 33,124 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- PRaTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary SarcoidosisMeeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's meeting request to discuss its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis. The Type C meeting is scheduled for mid-April 202
- INSIDERSEC Form 4 filed by President and CEO Shukla Sanjay4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Broadfoot Jill Marie4 - aTYR PHARMA INC (0001339970) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Denyes Nancy4 - aTYR PHARMA INC (0001339970) (Issuer)
- SECaTyr Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - aTYR PHARMA INC (0001339970) (Filer)
- PRaTyr Pharma to Present at Piper Sandler 37th Annual Healthcare ConferenceSAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY. Details of the presentation appears below: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate: Tuesday, December 2, 2025Time: 1:00pm ESTLocation: New York, NYFormat: Fireside Chat In addition to the presentation, compa
- SECSEC Form 10-Q filed by aTyr Pharma Inc.10-Q - aTYR PHARMA INC (0001339970) (Filer)
- SECaTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - aTYR PHARMA INC (0001339970) (Filer)
- PRaTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate UpdateResults reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of fi
- INSIDERDirector Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)
- PRaTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King's Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the P
- ANALYSTaTyr Pharma downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded aTyr Pharma from Outperform to Sector Perform and set a new price target of $1.50